Mesoblast Limited

NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that it hosted a key opinion leader webinar this week titled “The Graft-versus-Host Disease Exchange - Expert Perspectives on Evolving Clinical Practice” with leading pediatric transplant and cellular-therapy specialist Dr. Susan Prockop, Associate Professor, Harvard Medical School; Attending Physician & Director, Boston Children's Hospital. Dr. Prockop provided an overview of Ryoncil® (remestemcel-L-rknd)1 as a new treatment paradigm in the management of acute graft-versus-host disease, its use as first line after steroids, highlighted case studies, and discussed results from pivotal trials.

NEW YORK, Nov. 01, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced rotational changes and retirement of certain members of its Board, and reiterated its intention to add new members with the requisite global commercial experience in the biopharmaceutical sector in line with its next phase of commercial delivery and growth.

NEW YORK, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided its activity report for the first fiscal quarter ended September 30, 2026.

Mesoblast's Ryoncil provides commercial validation for its cell-therapy platform while helping finance additional development. Ryoncil's ongoing growth should also help finance MESO's remaining pipeline, in particular Rexlemestrocel-L. You see, Rexlemestrocel-L could give MESO another larger TAM as a back-pain franchise if its pivotal data support approval.